VVOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vivos Therapeutics Inc (VVOS) is not a strong buy at this moment for a beginner investor with a long-term focus. The company has shown revenue growth, but its financial performance is weak with consistent losses and missed earnings expectations. Technical indicators are neutral, and there are no significant trading trends or proprietary trading signals to suggest immediate action. Given the lack of positive catalysts and the investor's preference for long-term stability, holding off on this stock is recommended.
The MACD is slightly positive but contracting, RSI is neutral at 36.669, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.124) but lacks momentum for a breakout.
Revenue increased by 16% in 2025, driven by acquisitions and increased sleep testing services.
The company reported a full-year net loss of $21.17 million in 2025, missed EPS expectations, and faced rising operating costs. Gross margin declined YoY, and the stock has an 80% chance of a slight decline in the next day.
In 2025/Q3, revenue increased by 75.73% YoY to $6.78 million, but net income remained negative at -$5.4 million. EPS improved slightly but is still negative at -0.49. Gross margin dropped to 52.38%, down 7.59% YoY.
No analyst rating or price target changes available.
